<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010081630">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="normal" font="default" size="100%">Galy, A.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Ciaffi, L.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Le Moing, V.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Eymard-Duvernay, Sabrina</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Abessolo, H.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Toby, R.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Ayangma, L.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Le Gac, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Mpoudi-Etame, M.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Koulla-Shiro, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Delaporte, Eric</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Cournil, Amandine</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>Incidence of infectious morbidity events after second-line antiretroviral therapy initiation in HIV-infected adults in Yaoundé, Cameroon</title>
        <secondary-title>Antiviral Therapy</secondary-title>
      </titles>
      <pages>547-552</pages>
      <keywords>
        <keyword>CAMEROUN</keyword>
        <keyword>YAOUNDE</keyword>
      </keywords>
      <dates>
        <year>2016</year>
      </dates>
      <call-num>fdi:010081630</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>Antiviral Therapy</full-title>
      </periodical>
      <isbn>1359-6535</isbn>
      <accession-num>ISI:000396089600010</accession-num>
      <number>6</number>
      <electronic-resource-num>10.3851/imp3030</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010081630</url>
        </related-urls>
        <pdf-urls>
          <url>https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers21-03/010081630.pdf</url>
        </pdf-urls>
      </urls>
      <volume>21</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>Background: Since antiretroviral therapy (ART), HIV-infected individuals experience mainly non-AIDS-related conditions, among which infectious events are prominent. We aimed to estimate incidence and describe overall spectrum of infectious events, including all grade events, among HIV-1-infected adults failing first-line ART in Yaounde, Cameroon. Methods: All patients from Cameroon enrolled in the second-line ART 2LADY trial (ANRS12169) were included in this secondary analysis. Medical files were reviewed with predefined criteria for diagnosis assessment. Incidence rates (IR) were estimated per 100 person-years (% PY). Results: A total of 302 adult patients contributing 840 PY experienced 596 infectious events (IR 71% PY). Only 29 (5%) events were graded as severe. Most frequent infections were upper respiratory tract infections (15% PY), diarrhoea (9% PY) and malaria (9% PY). A total of 369 (62%) infections occurred during the first year (IR 130% PY) followed by a persistent lower incidence during the following 3 years. Higher IR were observed in patients with CD4(+) T-cell count &lt; 200 cells/mm(3) for all infectious events except for mycobacterial and parasitic infections. IR of viral, bacterial and parasitic infectious events were lower in case of co-trimoxazole use in patients with CD4(+) T-cell count &lt; 200 cells/mm(3). Conclusions: Infectious events are common and mainly occur during the first year after treatment initiation. Second-line ART initiation had a positive impact on the entire spectrum of infectious morbidity.</abstract>
      <custom6>052 ; 050</custom6>
      <custom1>UR233</custom1>
      <custom7>Cameroun</custom7>
    </record>
  </records>
</xml>
